PL364936A1 - Sposoby leczenia zaburzeń psychicznych z zastosowaniem bioaktywnych metabolitów gepironu - Google Patents
Sposoby leczenia zaburzeń psychicznych z zastosowaniem bioaktywnych metabolitów gepironuInfo
- Publication number
- PL364936A1 PL364936A1 PL00364936A PL36493600A PL364936A1 PL 364936 A1 PL364936 A1 PL 364936A1 PL 00364936 A PL00364936 A PL 00364936A PL 36493600 A PL36493600 A PL 36493600A PL 364936 A1 PL364936 A1 PL 364936A1
- Authority
- PL
- Poland
- Prior art keywords
- gepirone
- psychological disorders
- treatment
- bioactive metabolites
- metabolites
- Prior art date
Links
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical class O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 title abstract 3
- 230000000975 bioactive effect Effects 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- -1 3-OH gepirone (4 Chemical class 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960000647 gepirone Drugs 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17268499P | 1999-12-20 | 1999-12-20 | |
| US09/709,741 US6534507B1 (en) | 1999-12-20 | 2000-11-13 | Methods for treating psychological disorders using bioactive metabolites of gepirone |
| PCT/US2000/034131 WO2001045687A2 (en) | 1999-12-20 | 2000-12-18 | Use of bioactive metabolites of gepirone for the treatment of psychological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL364936A1 true PL364936A1 (pl) | 2004-12-27 |
| PL200378B1 PL200378B1 (pl) | 2008-12-31 |
Family
ID=26868346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL364936A PL200378B1 (pl) | 1999-12-20 | 2000-12-18 | Zastosowanie metabolitu gepironu do wytwarzania leku do poprawienia stanu psychologicznego u ssaka oraz kompozycja zawierająca metabolit gepironu |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6534507B1 (pl) |
| EP (1) | EP1242061B1 (pl) |
| JP (1) | JP4236407B2 (pl) |
| KR (1) | KR100602976B1 (pl) |
| CN (1) | CN1411375A (pl) |
| AT (1) | ATE294572T1 (pl) |
| AU (1) | AU776409B2 (pl) |
| CA (1) | CA2395458C (pl) |
| CZ (1) | CZ300429B6 (pl) |
| DE (1) | DE60019968T2 (pl) |
| ES (1) | ES2241683T3 (pl) |
| HU (1) | HU228963B1 (pl) |
| IL (2) | IL150222A0 (pl) |
| MX (1) | MXPA02006146A (pl) |
| NO (1) | NO323304B1 (pl) |
| NZ (1) | NZ519554A (pl) |
| PL (1) | PL200378B1 (pl) |
| PT (1) | PT1242061E (pl) |
| RU (1) | RU2282448C2 (pl) |
| WO (1) | WO2001045687A2 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001295478A1 (en) * | 2000-08-22 | 2002-03-04 | Akzo Nobel N.V. | Active metabolite of gepirone |
| US20040000689A1 (en) * | 2002-06-28 | 2004-01-01 | Erh-Kun Lai | Dual-bit MONOS/SONOS memory structure with non-continuous floating gate |
| US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
| WO2004014309A2 (en) * | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Improved process for hydroxyazapirones |
| US20050004105A1 (en) * | 2003-01-29 | 2005-01-06 | Emer Leahy | Treatment for a attention-deficit hyperactivity disorder |
| TW200521125A (en) * | 2003-11-18 | 2005-07-01 | Bristol Myers Squibb Co | Continuous process for producing hydroxyazapirones by oxidation |
| WO2006052227A1 (en) * | 2004-11-05 | 2006-05-18 | Fabre-Kramer Holdings, Inc. | High-dosage extended-release formulation of gepirone |
| CN102026639A (zh) * | 2008-05-08 | 2011-04-20 | 法布雷-克雷默医药公司 | 用于治疗注意力缺陷障碍和性功能障碍的3-羟基吉哌隆 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4423049A (en) | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
| US5185329A (en) * | 1988-08-30 | 1993-02-09 | Bristol-Myers Squibb Company | Method for treatment of substance addiction |
| JP2785879B2 (ja) * | 1989-05-31 | 1998-08-13 | ジ・アップジョン・カンパニー | 治療学的に有用な2―アミノテトラリン誘導体 |
| US4956368A (en) | 1989-07-24 | 1990-09-11 | Bristol-Myers Company | Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione |
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
-
2000
- 2000-11-13 US US09/709,741 patent/US6534507B1/en not_active Expired - Lifetime
- 2000-12-18 NZ NZ519554A patent/NZ519554A/en not_active IP Right Cessation
- 2000-12-18 JP JP2001546426A patent/JP4236407B2/ja not_active Expired - Lifetime
- 2000-12-18 DE DE60019968T patent/DE60019968T2/de not_active Expired - Lifetime
- 2000-12-18 HU HU0301831A patent/HU228963B1/hu unknown
- 2000-12-18 AT AT00986449T patent/ATE294572T1/de active
- 2000-12-18 ES ES00986449T patent/ES2241683T3/es not_active Expired - Lifetime
- 2000-12-18 EP EP00986449A patent/EP1242061B1/en not_active Expired - Lifetime
- 2000-12-18 CZ CZ20022137A patent/CZ300429B6/cs not_active IP Right Cessation
- 2000-12-18 KR KR1020027007927A patent/KR100602976B1/ko not_active Expired - Lifetime
- 2000-12-18 IL IL15022200A patent/IL150222A0/xx unknown
- 2000-12-18 WO PCT/US2000/034131 patent/WO2001045687A2/en not_active Ceased
- 2000-12-18 RU RU2002119400/14A patent/RU2282448C2/ru active
- 2000-12-18 CA CA002395458A patent/CA2395458C/en not_active Expired - Lifetime
- 2000-12-18 PL PL364936A patent/PL200378B1/pl unknown
- 2000-12-18 MX MXPA02006146A patent/MXPA02006146A/es active IP Right Grant
- 2000-12-18 AU AU22687/01A patent/AU776409B2/en not_active Expired
- 2000-12-18 PT PT00986449T patent/PT1242061E/pt unknown
- 2000-12-18 CN CN00817455A patent/CN1411375A/zh active Pending
-
2002
- 2002-06-13 IL IL150222A patent/IL150222A/en active IP Right Grant
- 2002-06-19 NO NO20022954A patent/NO323304B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE294572T1 (de) | 2005-05-15 |
| DE60019968T2 (de) | 2006-02-02 |
| CA2395458C (en) | 2009-05-12 |
| HUP0301831A2 (hu) | 2003-09-29 |
| CZ20022137A3 (cs) | 2003-03-12 |
| NO20022954D0 (no) | 2002-06-19 |
| EP1242061A2 (en) | 2002-09-25 |
| DE60019968D1 (de) | 2005-06-09 |
| IL150222A (en) | 2009-09-22 |
| PL200378B1 (pl) | 2008-12-31 |
| PT1242061E (pt) | 2005-09-30 |
| RU2282448C2 (ru) | 2006-08-27 |
| KR100602976B1 (ko) | 2006-07-20 |
| CZ300429B6 (cs) | 2009-05-20 |
| IL150222A0 (en) | 2002-12-01 |
| AU776409B2 (en) | 2004-09-09 |
| WO2001045687A2 (en) | 2001-06-28 |
| JP4236407B2 (ja) | 2009-03-11 |
| RU2002119400A (ru) | 2004-01-27 |
| AU2268701A (en) | 2001-07-03 |
| ES2241683T3 (es) | 2005-11-01 |
| EP1242061B1 (en) | 2005-05-04 |
| NZ519554A (en) | 2005-01-28 |
| MXPA02006146A (es) | 2004-08-23 |
| NO20022954L (no) | 2002-06-19 |
| KR20020082470A (ko) | 2002-10-31 |
| NO323304B1 (no) | 2007-03-05 |
| US6534507B1 (en) | 2003-03-18 |
| CN1411375A (zh) | 2003-04-16 |
| CA2395458A1 (en) | 2001-06-28 |
| JP2004500362A (ja) | 2004-01-08 |
| WO2001045687A3 (en) | 2002-04-25 |
| HU228963B1 (en) | 2013-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1010I1 (pl) | ||
| MXPA04002825A (es) | Derivados de quinolina como antagonistas de neuropeptido y. | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| AR027528A1 (es) | Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos | |
| IL149496A (en) | Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract | |
| SI1185272T1 (en) | Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania | |
| AU2003300911A1 (en) | Heterocyclic compounds as ccr5 antagonists | |
| RU2001119054A (ru) | Калиевая соль (S)-омепразола | |
| WO2004010936A3 (en) | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| NO20022954D0 (no) | Anvendelse av bioaktive metabolitter av gepiron for behandling av psykologiske forstyrrelser | |
| MD523G2 (ro) | Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| EP1256344A4 (en) | MEDICINE AGAINST ENDOTHELIN-DISEASES | |
| AR015966A1 (es) | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito | |
| CA2464420A1 (en) | Dosage unit comprising a prostaglandin analog for treating constipation | |
| DE50211929D1 (en) | Pyrimidinderivate | |
| RU2002118304A (ru) | Способ подавления чувства страха | |
| PE20011004A1 (es) | Composicion de liberacion controlada de un inhibidor de fosfodiesterasa 4 | |
| CA2364178A1 (en) | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | |
| ES2089974A1 (es) | Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica. | |
| MY131878A (en) | Eplerenone crystalline form exhibiting enhanced dissolution rate | |
| ES2076894A1 (es) | Derivados de 2-(4-(4-azolibutil)-1-piperacinil)-5-hidroxipirimidina, su preparacion y su aplicacion como medicamentos. | |
| MY143571A (en) | Eplerenone crystalline form | |
| NZ535611A (en) | Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist | |
| MXPA03003980A (es) | Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos. |